Wednesday, July 8, 2026

biotech · Attention Deficit Hyperactivity Disorder · Vascular Ehlers-Danlos Syndrome · AYTU

AYTU BIOPHARMA

Aytu BioPharma is a biotech organization headquartered in Denver, USA. It trades on NYSE under ticker AYTU. Primary therapeutic focus areas include Attention Deficit Hyperactivity Disorder, Vascular Ehlers-Danlos Syndrom

Denver, USA HQ
2015 Founded
105 Employees
Public company Type
AYTU · NYSE Ticker
Company details
Status
Public
HQ
Denver, USA
Founded
2015
Employees
105
Programs
3
Drugs
5
Patents
4
Clinical program

ADZENYS XR-ODT

Approved · small molecule · Attention Deficit Hyperactivity Disorder

ADZENYS XR-ODT for Attention Deficit Hyperactivity Disorder is a Approved program (small_molecule) at AYTU BIOPHARMA, INC with 1 ClinicalTrials.gov record(s).

← All AYTU BIOPHARMA, INC projects Approved small molecule terminated

Internal code NT0202.1009

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AYTU BIOPHARMA, INC
Phase
Approved
Modality
small_molecule
Indication
Attention Deficit Hyperactivity Disorder
Status
terminated
Trials
1